New cell therapy aims to regenerate scarred lungs
NCT ID NCT06081621
Summary
This study tested whether a new cell therapy called REGEND001 could help people with idiopathic pulmonary fibrosis (IPF), a serious disease that scars the lungs. In this Phase 2 trial, 23 patients were randomly assigned to receive either the cell therapy or a placebo to compare their effects. The main goal was to see if the treatment safely improved how well the lungs transfer oxygen into the blood over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
Renji Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, 200127, China
-
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, 361021, China
Conditions
Explore the condition pages connected to this study.